1. Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs

   • Tian-Lu Cheng
   • Bing-Mae Chen
   • S. R. Roffler

   ORIGINAL ARTICLE Pages: 305 - 315

2. Interleukin-1α synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity

   • Wei-Dong Yu
   • Ming-Jei Chang
   • C. S. Johnson

   ORIGINAL ARTICLE Pages: 316 - 322

3. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy

   • G. A. Pietersz
   • L. Wenjun
   • Ian F. C. McKenzie

   ORIGINAL ARTICLE Pages: 323 - 328

4. Quantitative analysis of cytokine mRNA expression in peripheral blood mononuclear cells following treatment with interleukin-2

   • Masashi Adachi
   • Hiroshi Inoue
   • T. Akiyoshi

   ORIGINAL ARTICLE Pages: 329 - 334

5. Variable expression of tumor necrosis factor α in human malignant melanoma localized by in situ hybridization for mRNA

   • Cecilia Bergenwald
   • Gunilla Westermark
   • B. Sander

   ORIGINAL ARTICLE Pages: 335 - 340

6. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge

   • Ian F. Hermans
   • Angela Daish
   • F. Ronchese

   ORIGINAL ARTICLE Pages: 341 - 347

7. A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma

   • A. Piga
   • Paolo Giordani
   • Riccardo Cellerino

   SHORT COMMUNICATION Pages: 348 - 351